Elizabeth Garrett-Mayer to Survival Rate
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Survival Rate.
Connection Strength
0.330
-
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2012 Jan 05; 119(1):55-63.
Score: 0.077
-
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012 Nov; 97(11):1736-42.
Score: 0.020
-
Cigarette smoking and the risk of dying from tobacco-related malignancies by race. Anticancer Res. 2011 Nov; 31(11):3891-5.
Score: 0.019
-
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9.
Score: 0.018
-
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010 Aug; 33(4):346-52.
Score: 0.018
-
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 2010 Jun; 28(5):340-8.
Score: 0.018
-
Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. 2010 Feb; 120(2):236-42.
Score: 0.017
-
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr; 31(4):493-502.
Score: 0.016
-
Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008 Jul; 118(7):1180-5.
Score: 0.015
-
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep; 32(9):1439-47.
Score: 0.015
-
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 01; 25(25):3965-70.
Score: 0.014
-
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
Score: 0.014
-
Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007 Jul; 106(1):82-8.
Score: 0.014
-
Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg. 2007 Feb; 142(2):126-32; discussion 133.
Score: 0.014
-
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb 15; 109(4):1387-94.
Score: 0.014
-
Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006 Sep; 12(9):965-72.
Score: 0.014
-
Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol Sci. 2005 Dec; 88(2):562-75.
Score: 0.013